Novartis is touting a pipeline with 76 drugs in clinical development, including 50 that are in Phase II or III. The pharma giant's biggest drug lead is Galvus, which Novartis is close to filing with the FDA. The oral MS therapy FTY720 is slated for late-stage trials in Europe with talks in the U.S. underway to gain FDA clearance for Phase III. Novartis has been bumping up its market share recently, growing from 5 percent for the first 11 months of 2004 to 5.3 percent for the same period last year.
- check out this AFX article [1]
ALSO: Singapore's MerLion Pharmaceuticals has partnered with the Novartis Institute for Tropical Diseases on a new therapy for dengue fever. Report [2]
Links:
[1] http://www.forbes.com/markets/feeds/afx/2006/01/19/afx2460492.html
[2] http://www.forbes.com/home/feeds/afx/2006/01/19/afx2460378.html